OpenAI acquires Orchestra Bio to bring AI agents into drug development
SiliconANGLE
Read the full article
OpenAI has acquired Orchestra Bio, a startup specializing in AI agents for drug development, integrating its technology into OpenAI's Rosalind life sciences unit to accelerate pharmaceutical research and clinical trial management. Orchestra's AI agents help monitor studies, manage finances, and optimize clinical trial scheduling, aiming to reduce the lengthy drug approval timeline. The acquisition complements OpenAI's existing Rosalind platform, already used by companies like Novo Nordisk and ,
